Home > Insider Trading > Filing (0001225208-25-004799)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1099800	Edwards Lifesciences Corp	EW	Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)	364316614

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1665141	J Bernard Zovighian	One Edwards Way Irvine CA 92614	Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2025-05-03	527	$75.65	58,827	No	4	F	Direct
Common Stock	Disposition	2025-05-04	543	$75.65	58,284	No	4	F	Direct
Common Stock	Acquisiton	2025-05-05	7,462	$45.28	65,746	No	4	M	Direct
Common Stock	Disposition	2025-05-05	1,482	$0.00	64,264	No	4	G	Direct
Common Stock	Disposition	2025-05-05	5,980	$74.91	58,284	No	4	S	Direct
Common Stock	Disposition	2025-05-06	1,036	$0.00	57,248	No	4	G	Direct
Common Stock	Acquisiton	2025-05-05	1,482	$0.00	11,918	No	4	G	Indirect	By Trust
Common Stock	Acquisiton	2025-05-06	1,036	$0.00	12,954	No	4	G	Indirect	By Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	F	Direct
No	4	F	Direct
No	4	M	Direct
No	4	G	Direct
No	4	S	Direct
No	4	G	Direct
No	4	G	Indirect	By Trust
No	4	G	Indirect	By Trust

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Acquire)	Disposition	2025-05-05	7,462	$0.00	7,462	$45.28

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2025-05-16	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	3,606	Indirect	401(k)

Footnotes

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2024.
This transaction was executed in multiple trades at prices ranging from $74.67 to $75.15 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
These options were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one yearafter the grant date in four equal annual installments.